Welcome to the DED Outlook: Understanding the Disease and Treatments on the Horizon webinar. The live course has ended. If you participated in the course on April 27, 2021 at 8pm ET, you may proceed to the post-test and claim your credit. Please select "Next Page" below.
If you are experiencing any issues please contact info@evolvemeded.com.
As new and novel approaches to the treatment of dry eye come to fruition, it is important for eye care providers to stay up to date regarding the options available for rapid symptom relief and for individualizing treatment regimens for their patients. This live symposium will focus on those topics and more, including data on the significance of the trigeminal nerve in ocular surface disorders.
This activity is supported by an unrestricted educational grant from Oyster Point Pharma.
Upon completion of this activity, the participant should be able to:
Evolve Medical Education LLC (Evolve) is an approved COPE administrator.
This course is approved for 1.0 hours for Optometrists.
Course #: 72321-AS
Activity #: 121610
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Damon Dierker, OD, FAAO
Director, Optometric Services
Eye Surgeons of Indiana
Indianapolis, IN
Patrick M. Vollmer, OD, FAAO
Director of Clinic & Research Divisions
Vita Eye Clinic
Shelby, NC
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Damon Dierker, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Bio-Tissue, Carl Zeiss Meditec, Eyevance, Glaukos, Johnson & Johnson, Kala, Lumenis, MacuLogic, Notal Vision, Novartis, Sight Sciences, and Sun Pharma. Grant/Research Support: Allergan, Ocular Therapeutix, and Tarsus. Speaker’s Bureau: Alcon, Allergan, Bio-Tissue, Glaukos, Lumenis, MacuLogic, MacuHealth, Notal Vision, Novartis, Osmotica, Scope, and TearLab.
Patrick M. Vollmer, OD, FAAO, has had no financial agreement or affiliation with a commercial interest during the past year.
EDITORIAL SUPPORT DISCLOSURES
The Evolve staff and planners have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Oyster Point Pharma.
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!